Ascendis Pharma A/S Equity And Liabilities
Ascendis Pharma A/S (ASND) had Equity And Liabilities of EUR 1.30 billion as of 2025-12-31, per its 20-F filed 2026-02-11.
Financial Statements › Notes
ifrs-full:EquityAndLiabilities · last filed 2026-02-11
- 2025-12-31: Equity And Liabilities 1.30B EUR.
- 2025-09-30: Equity And Liabilities 1.15B EUR.
- 2025-06-30: Equity And Liabilities 1.09B EUR.
- 2025-03-31: Equity And Liabilities 1.06B EUR.
| Period end | Equity And Liabilities |
|---|---|
| 2025-12-31 | 1.30B EUR 20-F · filed 2026-02-11 |
| 2025-09-30 | 1.15B EUR 6-K · filed 2025-11-12 |
| 2025-06-30 | 1.09B EUR 6-K · filed 2025-08-07 |
| 2025-03-31 | 1.06B EUR 6-K · filed 2025-05-01 |
| 2024-12-31 | 1.18B EUR 20-F · filed 2026-02-11 |
| 2024-09-30 | 1.09B EUR 6-K · filed 2024-11-14 |
| 2024-06-30 | 758.30M EUR 6-K · filed 2024-09-03 |
| 2024-03-31 | 802.50M EUR 6-K · filed 2024-05-02 |
| 2023-12-31 | 825.59M EUR 20-F · filed 2025-02-12 |
| 2023-09-30 | 873.21M EUR 6-K · filed 2023-11-07 |
| 2023-06-30 | 823.82M EUR 6-K · filed 2023-09-05 |
| 2023-03-31 | 966.27M EUR 6-K · filed 2023-04-27 |
| 2023-01-01 | 1.09B EUR 20-F · filed 2025-02-12 |
| 2022-12-31 | 1.09B EUR 20-F · filed 2024-02-07 |
| 2022-09-30 | 1.27B EUR 6-K · filed 2022-11-02 |
| 2022-06-30 | 1.33B EUR 6-K · filed 2022-08-10 |
| 2022-03-31 | 1.38B EUR 6-K · filed 2022-05-11 |
| 2021-12-31 | 1.08B EUR 20-F · filed 2023-02-16 |
| 2021-09-30 | 1.21B EUR 6-K · filed 2021-11-10 |
| 2021-06-30 | 851.85M EUR 6-K · filed 2021-08-27 |
| 2021-03-31 | 965.31M EUR 6-K · filed 2021-05-27 |
| 2020-12-31 | 979.79M EUR 20-F · filed 2022-03-02 |
| 2020-09-30 | 1.05B EUR 6-K · filed 2020-11-12 |
| 2020-06-30 | 560.61M EUR 6-K · filed 2020-08-27 |
| 2020-03-31 | 621.41M EUR 6-K · filed 2020-05-19 |
| 2019-12-31 | 676.73M EUR 20-F · filed 2021-03-10 |
| 2019-09-30 | 734.96M EUR 6-K · filed 2019-11-18 |
| 2019-06-30 | 767.16M EUR 6-K · filed 2019-08-28 |
| 2019-03-31 | 761.94M EUR 6-K · filed 2019-05-30 |
| 2018-12-31 | 318.97M EUR 20-F · filed 2020-04-03 |
| 2018-09-30 | 335.23M EUR 6-K · filed 2018-11-28 |
| 2018-06-30 | 368.86M EUR 6-K · filed 2018-08-29 |
| 2018-03-31 | 364.83M EUR 6-K · filed 2018-05-30 |
| 2017-12-31 | 210.98M EUR 20-F · filed 2019-04-03 |
| 2016-12-31 | 190.07M EUR 20-F · filed 2018-03-28 |